Heterogeneity-based stratification identifies CKMT2 as a prognostic marker in osteosarcoma
Frontiers in Cell and Developmental Biology · 25.05.2026 · 14
DOI: 10.3389/fcell.2026.1822741 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 25.05.2026. Verfasst von Xuesong Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Osteosarcoma (OS) is the most common primary malignant bone tumor. Intratumoral heterogeneity (ITH) contributes to therapy resistance and disease spread. Understanding the molecular structure and cellular groups contributing to ITH, as well as their clinical impacts, remains limited.
Methods
To build our investigation, we started by integrating single-cell transcriptomic data with multi-cohort transcriptomic datasets sourced from public repositories. Our bioinformatics pipeline was then designed to systematically unpack this information: first, we identified malignant cells by inferring their copy number variation (CNV); next, we assessed the degree of heterogeneity and defined distinct molecular subtypes; and finally, we conducted an in-depth analysis of the functional pathways mediating these heterogeneous characteristics. To sharpen the prognostic model linked to ITH, we employed machine learning to develop and validate a prognostic risk model for ten critical genes and performed both clinical and functional assays. Meanwhile, we validated the pro-tumorigenic role and therapeutic viability of CKMT2 through immunohistochemistry (IHC) and a series of in vitro functional assays.
Results
Analysis of transcriptomic data from single-cells highlighted ten primary cell types in osteosarcoma. The dominant malignant population as per CNV analysis has been identified as osteoblastic cells (OBs). The subsequent subclassification of OB led to the discovery of five malignant subtypes, resulting in stratification of high and low ITH. Consensus clustering, driven by the differential expression genes discovered in ITH, successfully divided the population into two distinct molecular subtypes. These subtypes exhibited a robust correlation with clinical prognosis and immune infiltration in multiple independent cohorts. Through machine learning modeling, we identified a highly promising therapeutic target, Creatine Kinase Mitochondrial 2 (CKMT2), and performed both clinical and functional assays. IHC validated high CKMT2 expression in tumor tissues corresponding to clinical stage, and in vitro CKMT2 knockdown significantly decreased OS cell proliferation and colony formation.
Conclusion
This study provides a systematic map of osteosarcoma’s ITH landscape, identifying distinct molecular subtypes with varying clinical outcomes and immune profiles. CKMT2 is established as a key driver of osteosarcoma progression, serving both as a prognostic biomarker and a potential therapeutic target.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.
- Department of Urology, Shandong Cancer Hospital and Institute, Jinan, China.
- Department of Spine, East Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Orthopedic Surgery, Institute of Digital Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- Department of Interventional Radiology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.
- Department of Orthopedics, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Zitieren
APA
Li, X., Li, G., Peng, T., Qiu, J., Li, S., Wang, J., & Zhang, J. (2026). Heterogeneity-based stratification identifies CKMT2 as a prognostic marker in osteosarcoma. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1822741
Vancouver
Li X, Li G, Peng T, Qiu J, Li S, Wang J, et al. Heterogeneity-based stratification identifies CKMT2 as a prognostic marker in osteosarcoma. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1822741
BibTeX
@article{Li2026,
author = {Li, Xuesong and Li, Guanghao and Peng, Tianchou and Qiu, Junjun and Li, Shengwei and Wang, Jingfu and Zhang, Jin},
title = {Heterogeneity-based stratification identifies CKMT2 as a prognostic marker in osteosarcoma},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1822741}
}
EUVIMED